Advanced search
Publication Cover
Drug Delivery Volume 24, 2017 - Issue 1
Submit an article Journal homepage
2,760
Views
20
CrossRef citations to date
0
Altmetric
Research Article

Novel CD123-aptamer-originated targeted drug trains for selectively delivering cytotoxic agent to tumor cells in acute myeloid leukemia theranostics

Haibin Wua Shaanxi Institute of Pediatric Diseases, Xi’an Children’s Hospital, Xi’an, Shaanxi, People’s Republic of China; ;b Key laboratory of Environment and Genes Related to Diseases, Ministry of Education, Xi’an Jiaotong University Health Science Center, Xi’an, Shaanxi, People’s Republic of China; View further author information
,
Meng Wangc Department of Orthopedics, The No.11 Hospital of PLA, YiNing, XinJiang, People’s Republic of China; View further author information
,
Bo Daid Shaanxi Center for Stem Cell Application Engineering Research, Xi’an, Shaanxi, People’s Republic of China; ;e Shaanxi Key Laboratory of Ischemic Cardiovascular Disease, Institute of Basic and Translational Medicine, Xi’an Medical University, Xi’an, Shaanxi, People’s Republic of China; View further author information
,
Yanmin Zhanga Shaanxi Institute of Pediatric Diseases, Xi’an Children’s Hospital, Xi’an, Shaanxi, People’s Republic of China; View further author information
,
Ying Yanga Shaanxi Institute of Pediatric Diseases, Xi’an Children’s Hospital, Xi’an, Shaanxi, People’s Republic of China; View further author information
,
Qiao Lif Clinical Laboratory, Xi’an Children’s Hospital, Xi’an, Shaanxi, People’s Republic of ChinaView further author information
,
Mingyue Duana Shaanxi Institute of Pediatric Diseases, Xi’an Children’s Hospital, Xi’an, Shaanxi, People’s Republic of China; View further author information
,
Xi Zhanga Shaanxi Institute of Pediatric Diseases, Xi’an Children’s Hospital, Xi’an, Shaanxi, People’s Republic of China; View further author information
,
Xiaomei Wanga Shaanxi Institute of Pediatric Diseases, Xi’an Children’s Hospital, Xi’an, Shaanxi, People’s Republic of China; View further author information
,
Anmao Lia Shaanxi Institute of Pediatric Diseases, Xi’an Children’s Hospital, Xi’an, Shaanxi, People’s Republic of China; View further author information
&
Liyu Zhanga Shaanxi Institute of Pediatric Diseases, Xi’an Children’s Hospital, Xi’an, Shaanxi, People’s Republic of China; ;b Key laboratory of Environment and Genes Related to Diseases, Ministry of Education, Xi’an Jiaotong University Health Science Center, Xi’an, Shaanxi, People’s Republic of China; Correspondence[email protected] [email protected]
View further author information
 show all
Pages 1216-1229 | Received 22 Jun 2017, Accepted 11 Aug 2017, Published online: 28 Aug 2017

Related Research Data

The biomarkers of leukemia stem cells in acute myeloid leukemia.
Source: AME Publishing Company
Targeted delivery of etoposide to cancer cells by folate-modified nanostructured lipid drug delivery system
Source: Informa UK Limited
In vitro and in vivo evaluation of anti-nucleolin-targeted magnetic PLGA nanoparticles loaded with doxorubicin as a theranostic agent for enhanced targeted cancer imaging and therapy
Source: Elsevier BV
Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models.
Source: American Association for Cancer Research (AACR)
Enhanced growth inhibition of prostate cancer in vitro and in vivo by a recombinant adenovirus-mediated dual-aptamer modified drug delivery system
Source: Elsevier BV
CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells
Source: American Society for Clinical Investigation
New immunotoxins targeting CD123, a stem cell antigen on acute myeloid leukemia cells.
Source: Ovid Technologies (Wolters Kluwer Health)
Oligonucleotide aptamers: potential novel molecules against viral hepatitis
Source: Medknow
CD123 and its potential clinical application in leukemias.
Source: Elsevier BV
T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia.
Source: Ovid Technologies (Wolters Kluwer Health)
Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase
Source: American Association for the Advancement of Science (AAAS)
Rational Combinations of Targeted Agents in AML
Source: MDPI AG
CD123 redirected multiple virus-specific T cells for acute myeloid leukemia
Source: Elsevier BV
A novel strategy to achieve effective drug delivery: exploit cells as carrier combined with nanoparticles.
Source: Taylor & Francis Group
Therapeutic applications of synthetic nucleic acid aptamers
Source: Elsevier BV
Future prospects of therapeutic clinical trials in acute myeloid leukemia
Source: Future Medicine Ltd
The blind men and the AML elephant: can we feel the progress?
Source: Springer Science and Business Media LLC
Chitosan-modified PLGA nanoparticles tagged with 5TR1 aptamer for in vivo tumor-targeted drug delivery
Source: Elsevier BV
Self-Assembled Multivalent DNA Nanostructures for Noninvasive Intracellular Delivery of Immunostimulatory CpG Oligonucleotides
Source: American Chemical Society (ACS)
Design of a novel curcumin-soybean phosphatidylcholine complex-based targeted drug delivery systems
Source: Taylor & Francis Group
Aptamer-Conjugated Chitosan-Anchored Liposomal Complexes for Targeted Delivery of Erlotinib to EGFR-Mutated Lung Cancer Cells
Source: Springer Science and Business Media LLC
The safety and efficacy of vosaroxin in patients with first relapsed or refractory acute myeloid leukemia - a critical review.
Source: Informa UK Limited
Novel therapeutic options in Acute Myeloid Leukemia
Source: The Authors. Published by Elsevier Ltd.
Aptamer-Drug Conjugates of Active Metabolites of Nucleoside Analogs and Cytotoxic Agents Inhibit Pancreatic Tumor Cell Growth
Source: Elsevier BV
Selection of single-stranded DNA molecules that bind and inhibit human thrombin.
Source: Springer Science and Business Media LLC
Development of a novel engineered antibody targeting human CD123
Source: Elsevier BV
Mechanism of drug resistance in relation to site of metastasis: Meta-analyses of randomized controlled trials in advanced breast cancer according to anticancer strategy.
Source: Elsevier BV

Linking provided by 

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.